The American Journal of Medicine
Volume 123, Issue 11 , Pages 1001-1006 , November 2010

Inhaled Corticosteroids and the Risks of Diabetes Onset and Progression

  • Samy Suissa, PhD

      Affiliations

    • Center for Clinical Epidemiology, Lady Davis Research Institute, Jewish General Hospital, Montreal, Quebec, Canada
    • Department of Epidemiology and Biostatistics and Department of Medicine, McGill University, Montreal, Quebec, Canada
    • Corresponding Author InformationRequests for reprints should be addressed to Samy Suissa, PhD, Centre for Clinical Epidemiology, Jewish General Hospital, 3755 Cote Ste-Catherine, Montreal, Québec H3T 1E2, Canada
    • ,
  • Abbas Kezouh, PhD

      Affiliations

    • Center for Clinical Epidemiology, Lady Davis Research Institute, Jewish General Hospital, Montreal, Quebec, Canada
    • ,
  • Pierre Ernst, MD, MSc

      Affiliations

    • Center for Clinical Epidemiology, Lady Davis Research Institute, Jewish General Hospital, Montreal, Quebec, Canada
    • Department of Epidemiology and Biostatistics and Department of Medicine, McGill University, Montreal, Quebec, Canada

References 

  1. Postma DS, Calverley P. Inhaled corticosteroids in COPD: a case in favour. Eur Respir J. 2009;34:10–12
  2. Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur Respir J. 2009;34:13–16
  3. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532–555
  4. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789
  5. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177:19–26
  6. Garbe E, LeLorier J, Boivin JF, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA. 1997;277:722–727
  7. Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. [published erratum appears in JAMA. 1998;280(21):1830] [see comments] JAMA. 1998;280:539–543
  8. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med. 1999;159(9):941–955
  9. Kelly HW, Nelson HS. Potential adverse effects of the inhaled corticosteroids. J Allergy Clin Immunol. 2003;112:469–478
  10. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med. 2007;176:162–166
  11. Chapman KR, Mannino DM, Soriano JB, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J. 2006;27:188–207
  12. Lacasse Y, Brooks D, Goldstein RS. Trends in the epidemiology of COPD in Canada, 1980 to 1995 (COPD and Rehabilitation Committee of the Canadian Thoracic Society). Chest. 1999;116:306–313
  13. Yach D, Hawkes C, Gould CL, Hofman KJ. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA. 2004;291:2616–2622
  14. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32:962–969
  15. Rana JS, Mittleman MA, Sheikh J, et al. Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care. 2004;27:2478–2484
  16. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:144–149
  17. Dendukuri N, Blais L, LeLorier J. Inhaled corticosteroids and the risk of diabetes among the elderly. Br J Clin Pharmacol. 2002;54(1):59–64
  18. Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med. 2002;17:717–720
  19. Slatore CG, Bryson CL, Au DH. The association of inhaled corticosteroid use with serum glucose concentration in a large cohort. Am J Med. 2009;122:472–478
  20. Breton MC, LeLorier J, Forget A, Blais L. Use of combination therapy in asthma: are they prescribed according to guidelines. Respir Med. 2007;101:1916–1923
  21. Ernst P, Baltzan M, Deschenes J, Suissa S. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J. 2006;27:1168–1174
  22. Suissa S, Baltzan M, Kremer R, Ernst P. Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med. 2004;169:83–88
  23. Akerman MJ, Calacanis CM, Madsen MK. Relationship between asthma severity and obesity. J Asthma. 2004;41:521–526
  24. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:1005–1012

 Funding: This research was funded by grants from the Canadian Institutes of Health Research, Boehringer-Ingelheim GmbH, and the Canadian Foundation for Innovation. The sponsors had no role in the design and conduct of the study, including data collection, management, analysis, interpretation, or in the preparation of the manuscript.

 Conflict of Interest: Samy Suissa has received speaker fees or has served on advisory boards for AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck, and Pfizer. Pierre Ernst has received speaker fees or has served on advisory boards for AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck Frosst Canada, Novartis, and Nycomed.

 Authorship: All authors participated in the preparation of the manuscript.

PII: S0002-9343(10)00648-0

doi: 10.1016/j.amjmed.2010.06.019

The American Journal of Medicine
Volume 123, Issue 11 , Pages 1001-1006 , November 2010

Article Tools

* Image Usage & Resolution